Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: local administration for dental anesthesia is excepted from S5. The exception is not general permission for all uses; retained in the future 2027 List. [1] [2]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
The reviewed 2016 UK Citanest-with-Octapressin product information describes felypressin combined with prilocaine for local dental infiltration and nerve blocks. Felypressin is the vasopressor component. [3]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
The combination carries risks from accidental intravascular injection and systemic local-anesthetic toxicity. Prilocaine-associated methemoglobinemia is a combination-product concern and should not be assigned to felypressin alone. [3]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
What remains uncertain
- The reviewed UK SmPC is dated 2016; current marketing availability was not established.
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12
- Dentsply Sirona Citanest with Octapressin UK SmPC ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.